|
|
|
|
|
|
|
M Tue W Th F |
|
8 September, 2026 |
|
|
sponsored by
|
|
|
|
Stop Searching Through COAs and Batch Records. Start Asking Them Questions.
|
| Katalyze digitizes COAs, paper batch records, and PDFs, then creates an ontology tailored to your operation and builds a knowledge graph connecting those records with relevant system data. Your teams can search that knowledge and ask questions in plain language, with every answer traceable to its original source. Built for GxP environments, Katalyze puts fragmented records to work across Yield Optimization, Deviation Investigation, and Raw Material Characterization, with your experts in control. |
|
|
|
|
|
|
|
|
|
|
|
|
|
The FDA's landmark approval of Revolution Medicines' new pancreatic cancer drug led to a flurry of interest from patients, but also concerns about covering the cost of treatment. One oncologist we spoke to, Arturo Loaiza-Bonilla, said that he sought to transition several patients off the company's expanded access program. OptumRx initially didn't allow the transition before later relenting, he said, which "speaks more about the timeliness of how denials can occur by automated or outdated systems, and how quickly they need to adapt to these novel therapies that are really helping patients." |
|
|
|
Zachary Brennan |
Senior Editor, Endpoints News
@ZacharyBrennan
|
|
|
|
|
|
|
by Andrew Dunn
|
Anthropic's newest job posting confirms the company's biotech dealmaking ambitions. The San Francisco tech giant is hiring for a corporate development lead in biopharma to... | |
|
|
|
|
|
|
by Nicole DeFeudis
|
Pharvaris claims it achieved “injectable-like efficacy” in a once-daily pill for a debilitating genetic disease. The experimental drug, an extended-release version of deucrictibant, is designed... | |
|
|
|
|
|
|
by Max Bayer
|
Amgen reported a key clinical win for its T cell engager platform, finding that Imdelltra combined with a checkpoint inhibitor helped patients with advanced lung... | |
|
|
|
|
|
|
by Ayisha Sharma, Elizabeth Cairns
|
During this year’s European Respiratory Society (ERS) annual meeting in Barcelona, companies such as Sanofi and AstraZeneca lifted the curtain on detailed results from trials... | |
|
|
|
|
|
|
by Anna Brown
|
LONDON — Sandoz is betting big on its newly formed biosimilar unit, as it reveals plans to grow its pipeline there by more than sevenfold... | |
|
|
|
|
|
|
|
